TRIP13 Antibody (A-7): sc-514285

TRIP13 Antibody (A-7) is a mouse monoclonal IgG1 kappa light chain antibody that detects TRIP13 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TRIP13 (A-7) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. TRIP13, also known as thyroid hormone receptor interactor 13 or 16E1BP, plays a crucial role in the regulation of gene expression as a transcription factor. TRIP13 interacts with the ligand-binding domain of thyroid hormone receptors, which are essential for mediating the effects of thyroid hormones on gene expression. Among TRIP proteins, TRIP13 uniquely does not require thyroid hormone for receptor interaction, suggesting a distinct regulatory mechanism. TRIP13 has been implicated in interactions with the human papillomavirus type 16 E1 protein, indicating a potential role in tumor suppression. TRIP13 consists of 432 amino acids and exists in two isoforms generated through alternative splicing, highlighting complexity and potential for diverse functional roles in cellular processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TRIP13 Antibody (A-7) References:

1. Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions.  |  Arias-Pulido, H., et al. 2002. Mol Cancer. 1: 3. PMID: 12392596
2. Mouse pachytene checkpoint 2 (trip13) is required for completing meiotic recombination but not synapsis.  |  Li, XC. and Schimenti, JC. 2007. PLoS Genet. 3: e130. PMID: 17696610
3. Insights into a Crucial Role of TRIP13 in Human Cancer.  |  Lu, S., et al. 2019. Comput Struct Biotechnol J. 17: 854-861. PMID: 31321001
4. TRIP13 regulates DNA repair pathway choice through REV7 conformational change.  |  Clairmont, CS., et al. 2020. Nat Cell Biol. 22: 87-96. PMID: 31915374
5. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.  |  Li, C., et al. 2021. J Clin Invest. 131: PMID: 34061780
6. Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells.  |  Hu, L., et al. 2023. Cell Death Discov. 9: 333. PMID: 37669963
7. TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis.  |  Chotiner, JY., et al. 2023. bioRxiv.. PMID: 37808842
8. TRIP13 - a potential drug target in cancer pharmacotherapy.  |  Jacob Bunu, S., et al. 2024. Bioorg Chem. 151: 107650. PMID: 39042962
9. TRIP13: A promising cancer immunotherapy target.  |  Jing, S., et al. 2024. Cancer Innov. 3: e147. PMID: 39398261
10. Role of TRIP13 in human cancer development.  |  Chen, C., et al. 2024. Mol Biol Rep. 51: 1088. PMID: 39436503
11. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor.  |  Lee, JW., et al. 1995. Mol Endocrinol. 9: 243-54. PMID: 7776974
12. Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins.  |  Yasugi, T., et al. 1997. J Virol. 71: 5942-51. PMID: 9223484

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TRIP13 Antibody (A-7) has 6 citations in a variety of scientific publications.

Primary antibodies like Anti-TRIP13 Antibody (A-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TRIP13 Antibody (A-7) Specifications

Alternate Product Name: TRIP13

Product Clone Name: A-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-180

Epitope Target: TRIP13

Epitope Species: human

Product Reactivity/Detection: TRIP13

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 6 citations in various scientific publications

Available Conjugates/Forms for TRIP13 Antibody (A-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred TRIP13 antibody is TRIP13 Antibody (C-4): sc-514314.